Crispr Therapeutics Ag Stock Total Debt
| CRSP Stock | USD 41.94 0.97 2.37% |
Crispr Therapeutics AG fundamentals help investors to digest information that contributes to Crispr Therapeutics' financial success or failures. It also enables traders to predict the movement of Crispr Stock. The fundamental analysis module provides a way to measure Crispr Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crispr Therapeutics stock.
As of 03/20/2025, Total Debt To Capitalization is likely to drop to 0.1. Crispr | Total Debt |
Crispr Therapeutics AG Company Total Debt Analysis
Crispr Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Crispr Therapeutics Total Debt | 223.69 M |
Most of Crispr Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crispr Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Crispr Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Crispr Therapeutics is extremely important. It helps to project a fair market value of Crispr Stock properly, considering its historical fundamentals such as Total Debt. Since Crispr Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crispr Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crispr Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Crispr Total Debt Historical Pattern
Today, most investors in Crispr Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Crispr Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Crispr Therapeutics total debt as a starting point in their analysis.
Crispr Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Crispr Net Debt
Based on the latest financial disclosure, Crispr Therapeutics AG has a Total Debt of 223.69 M. This is 91.87% lower than that of the Biotechnology sector and 31.13% lower than that of the Health Care industry. The total debt for all United States stocks is 95.79% higher than that of the company.
Crispr Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crispr Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics of similar companies.Crispr Therapeutics is currently under evaluation in total debt category among its peers.
Crispr Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Crispr Therapeutics from analyzing Crispr Therapeutics' financial statements. These drivers represent accounts that assess Crispr Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Crispr Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 10.1B | 5.8B | 3.2B | 3.3B | 3.0B | 2.3B | |
| Enterprise Value | 9.0B | 5.1B | 3.2B | 3.2B | 2.9B | 2.0B |
Crispr Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crispr Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crispr Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Crispr Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Crispr Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Crispr Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Crispr Therapeutics' value.| Shares | Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | Ecor1 Capital, Llc | 2024-12-31 | 1.4 M | Baker Bros Advisors Lp | 2024-12-31 | 1.3 M | Bank Of America Corp | 2024-12-31 | 1.2 M | Sr One Capital Management, Lp | 2024-12-31 | 1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 947.3 K | Loomis, Sayles & Company Lp | 2024-12-31 | 911 K | Balyasny Asset Management Llc | 2024-12-31 | 893.9 K | Ark Investment Management Llc | 2024-12-31 | 9 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M |
Crispr Fundamentals
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 1.83 B | ||||
| Shares Outstanding | 85.77 M | ||||
| Shares Owned By Insiders | 1.67 % | ||||
| Shares Owned By Institutions | 77.71 % | ||||
| Number Of Shares Shorted | 20.41 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 94.18 X | ||||
| Revenue | 35 M | ||||
| Gross Profit | (393.59 M) | ||||
| EBITDA | (466.57 M) | ||||
| Net Income | (366.25 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 223.69 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 22.53 X | ||||
| Cash Flow From Operations | (142.77 M) | ||||
| Short Ratio | 8.19 X | ||||
| Earnings Per Share | (4.34) X | ||||
| Price To Earnings To Growth | (0.21) X | ||||
| Target Price | 83.6 | ||||
| Number Of Employees | 393 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 3.51 B | ||||
| Total Asset | 2.24 B | ||||
| Retained Earnings | (1.37 B) | ||||
| Working Capital | 1.85 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
| Net Asset | 2.24 B |
About Crispr Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crispr Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.32 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.31 | DRRX | Durect Earnings Call This Week | PairCorr |
| 0.31 | DRTS | Alpha Tau Medical | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.